|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 31/08/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 31/12/2022 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 03/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 25/08/2016 |
Günter von Au
CHM | Chairman | 75 | 26/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +0.35% | +0.93% | +21.08% | +71.89% | 48.07B | ||
| -0.08% | -0.21% | +55.27% | +121.68% | 40.17B | ||
| +0.15% | +6.34% | +21.70% | +87.77% | 12.42B | ||
| +0.25% | -0.61% | -9.92% | +15.84% | 12.01B | ||
| +0.19% | 0.00% | +30.00% | +147.62% | 9.38B | ||
| +0.07% | +3.80% | +27.45% | +46.12% | 7.78B | ||
| +2.24% | +8.50% | +29.85% | +227.84% | 7.27B | ||
| +0.04% | +0.37% | +48.15% | -11.95% | 7.24B | ||
| -0.53% | -1.53% | -34.29% | +19.67% | 5.33B | ||
| Average | +0.27% | +1.12% | +21.03% | +80.72% | 15.54B | |
| Weighted average by Cap. | +0.22% | +0.16% | +28.47% | +87.13% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















